2NTX-99 is a novel small molecule that has been shown in vivo and in vitro to inhibit the synthesis and action of thromboxane (TXA2), enhance the production of prostacyclin (PGI2) and supply a pharmacological amount of nitric oxide (NO) to the vasculature. Nile believes that the unique activity profile of 2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.
More information on Nile can be found at http://www.nilethera.com.
Chief Financial Officer
Nile Therapeutics, Inc.
To the extent that statements in this press release are not strictly
historical, including statements as to business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future financial
conditions, future collaboration agreements, the success of Nile's product
development, events conditioned on stockholder or other approval, or
otherwise as to future events, all such statements are forward-looking, and
are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject
to certain risks and uncertainties that could cause actual results to
differ materially from the statements made. Examples of the risks and
uncertainties include, but are not limited to: the risk that we may not
successfully develop and market our products, and even if we do, we may not
become profitable; risks relating to the progress of our research and
development; risks relating to the rigorous regulatory approval process
required for any products that we may develop independently, with our
development partners or in connection with our collaboration arrangements;
the risk that changes in the national or international political and
regulatory environment may make it mor
|SOURCE Nile Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved